A Phase I Trial of Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Washington University School of Medicine
Summary
The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Pathologically proven diagnosis of unresectable or metastatic leiomyosarcoma or adipocytic sarcoma. * Progressed on at least 1 line of prior therapy and have received no more than 4 lines of prior therapy. * Measurable disease per RECIST 1.1. * At least 18 years of age. * ECOG performance status ≤ 1 * Adequate bone marrow and organ function within 14 days before first dose of study treatment as defined below: * Absolute neutrophil count ≥ 1.5 K/cumm without granulocyte colony-stimulating factor support within 2 weeks of collection * Platelets ≥ 100 K/cumm without tr…
Interventions
- DrugZanzalintinib
Supplied by Exelixis, Inc.
- DrugEribulin
1.1 mg/m\^2 dose.
Location
- Washington University School of MedicineSt Louis, Missouri